Bhutan vs Zimbabwe: Average cost of multi drug-resistant tuberculosis treatment
Bhutan
886 constant 2022 US$
in 2024
Zimbabwe
851 constant 2022 US$
in 2023
Bhutan rank
55th
Zimbabwe rank
57th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bhutan
- Zimbabwe
How they compare
Bhutan currently reports 886 constant 2022 US$ against 851 constant 2022 US$ in Zimbabwe, a difference of 35 constant 2022 US$.
The two have swapped places 4 times across 7 shared years of data; in 2017 it was Zimbabwe ahead.
Bhutan ranks 55th and Zimbabwe ranks 57th of 92 countries.
Across the 2 decades both report, Bhutan averaged higher in 1 and Zimbabwe in 1.
Head to head by decade
| Decade | Bhutan | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,204 constant 2022 US$ | 1,672 constant 2022 US$ | 468.33 constant 2022 US$ | Zimbabwe |
| 2020s | 859 constant 2022 US$ | 696.25 constant 2022 US$ | 162.75 constant 2022 US$ | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bhutan or Zimbabwe?
- Bhutan, at 886 constant 2022 US$ against 851 constant 2022 US$ in Zimbabwe as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bhutan and Zimbabwe?
- 35 constant 2022 US$, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Zimbabwe?
- 7 years are reported by both, from 2017 to 2023.
- How do Bhutan and Zimbabwe rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bhutan ranks 55th and Zimbabwe ranks 57th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.